Inhibition of interleukin-17 in axial spondyloarthritis spectrum

Affiliations

¹ Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London WC1B 5EH, UK; Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK. Electronic address: p.machado@ucl.ac.uk.

Comment

Pedro M Machado. Lancet. 2020.

. 2020 Jan 4;395(10217):6-8.

doi: 10.1016/S0140-6736(19)33047-8. Epub 2019 Dec 5.

¹ Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London WC1B 5EH, UK; Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK. Electronic address: p.machado@ucl.ac.uk.

No abstract available

Comment on

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group. Deodhar A, et al. Lancet. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5. Lancet. 2020. PMID: 31813637 Clinical Trial.